Entropy Technologies LP Has $1.80 Million Stake in TG Therapeutics, Inc. $TGTX

Entropy Technologies LP increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 822.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 60,415 shares of the biopharmaceutical company’s stock after purchasing an additional 53,867 shares during the quarter. Entropy Technologies LP’s holdings in TG Therapeutics were worth $1,801,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Danske Bank A S acquired a new stake in TG Therapeutics during the 3rd quarter worth $25,000. Optiver Holding B.V. boosted its position in shares of TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 732 shares during the last quarter. Bessemer Group Inc. boosted its position in shares of TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares during the last quarter. Hantz Financial Services Inc. grew its stake in shares of TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 573 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of TG Therapeutics in a research note on Wednesday, May 27th. Finally, Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $52.50.

TG Therapeutics Price Performance

Shares of TGTX opened at $50.30 on Tuesday. The stock has a 50 day simple moving average of $38.72 and a 200 day simple moving average of $33.24. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $50.60. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. The firm has a market capitalization of $7.70 billion, a PE ratio of 17.59 and a beta of 1.68.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The company had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business’s quarterly revenue was up 69.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.03 EPS. Sell-side analysts predict that TG Therapeutics, Inc. will post 1.51 EPS for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.